KRAS and neoplasm: They observed that the tumour with KRAS mutation had the worst local control rates, while combined KRAS and p53 mutations rendered the tumour highly radioresistant with extremely low 1-year LC rates of 20% (as opposed to 69.2% for the other cohort, p = 0.001).